TSPO Imaging in Glioblastoma Multiforme: A Direct Comparison Between 123I-CLINDE SPECT, 18F-FET PET, and Gadolinium-Enhanced MR Imaging

Per Jensen; Ling Feng; Ian Law; Claus Svarer; Gitte M Knudsen; Jens D Mikkelsen; Robin de Nijs; Vibeke A Larsen; Agnete Dyssegaard; Gerda Thomsen; Walter Fischer; Denis Guilloteau; Lars H Pinborg

doi:10.2967/jnumed.115.158998

TSPO Imaging in Glioblastoma Multiforme: A Direct Comparison Between ¹²³I-CLINDE SPECT, ¹⁸F-FET PET, and Gadolinium-Enhanced MR Imaging

Per Jensen, Ling Feng, Ian Law, Claus Svarer, Gitte M Knudsen, Jens D Mikkelsen, Robin de Nijs, Vibeke A Larsen, Agnete Dyssegaard, Gerda Thomsen, Walter Fischer, Denis Guilloteau, Lars H Pinborg

Department of Clinical Medicine

23 Citations (Scopus)

Abstract

Here we compare translocator protein (TSPO) imaging using 6-chloro-2-(4′-¹²³I-iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide SPECT (¹²³I-CLINDE) and amino acid transport imaging using O-(2-¹⁸F-fluoroethyl)-L-tyrosine PET (¹⁸F-FET) and investigate whether ¹²³I-CLINDE is superior to ¹⁸F-FET in predicting progression of glioblastoma multiforme (GBM) at follow-up. Methods: Three patients with World Health Organization grade IV GBM were scanned with ¹²³I-CLINDE SPECT, ¹⁸F-FET PET, and gadoliniumenhanced MR imaging. Molecular imaging data were compared with follow-up gadolinium-enhanced MR images or contrast-enhanced CT scans. Results: The percentage overlap between volumes of interest (VOIs) of increased ¹⁸F-FET uptake and ¹²³I-CLINDE binding was variable (12%-42%). The percentage overlap of MR imaging baseline VOIs was greater for ¹⁸F-FET (79%-93%) than ¹²³I-CLINDE (15%- 30%). In contrast, VOIs of increased contrast enhancement at followup compared with baseline overlapped to a greater extent with baseline ¹²³I-CLINDE VOIs than ¹⁸F-FET VOIs (21% vs. 8% and 72% vs. 55%). Conclusion: Our preliminary results suggest that TSPO brain imaging in GBM may be a useful tool for predicting tumor progression at followup and may be less susceptible to changes in blood-brain barrier permeability than ¹⁸F-FET. Larger studies are warranted to test the clinical potential of TSPO imaging in GBM, including presurgical planning and radiotherapy.

Original language	English
Journal	Journal of Nuclear Medicine
Volume	56
Issue number	9
Pages (from-to)	1386-90
Number of pages	5
ISSN	0161-5505
DOIs	https://doi.org/10.2967/jnumed.115.158998
Publication status	Published - 1 Sept 2015

Keywords

Aged
Bicyclo Compounds, Heterocyclic
Biomarkers, Tumor
Brain Neoplasms
Female
Fluorodeoxyglucose F18
Gadolinium
Glioblastoma
Humans
Image Interpretation, Computer-Assisted
Magnetic Resonance Imaging
Male
Middle Aged
Molecular Imaging
Radiopharmaceuticals
Receptors, GABA
Reproducibility of Results
Sensitivity and Specificity
Tissue Distribution
Tomography, Emission-Computed
Tyrosine

Access to Document

10.2967/jnumed.115.158998

1386.full.pdfFinal published version, 643 KB

Cite this

Jensen, P., Feng, L., Law, I., Svarer, C., Knudsen, G. M., Mikkelsen, J. D., de Nijs, R., Larsen, V. A., Dyssegaard, A., Thomsen, G., Fischer, W., Guilloteau, D., & Pinborg, L. H. (2015). TSPO Imaging in Glioblastoma Multiforme: A Direct Comparison Between ¹²³I-CLINDE SPECT, ¹⁸F-FET PET, and Gadolinium-Enhanced MR Imaging. Journal of Nuclear Medicine, 56(9), 1386-90. https://doi.org/10.2967/jnumed.115.158998

Jensen, P, Feng, L, Law, I, Svarer, C, Knudsen, GM, Mikkelsen, JD, de Nijs, R, Larsen, VA, Dyssegaard, A, Thomsen, G, Fischer, W, Guilloteau, D & Pinborg, LH 2015, 'TSPO Imaging in Glioblastoma Multiforme: A Direct Comparison Between ¹²³I-CLINDE SPECT, ¹⁸F-FET PET, and Gadolinium-Enhanced MR Imaging', Journal of Nuclear Medicine, vol. 56, no. 9, pp. 1386-90. https://doi.org/10.2967/jnumed.115.158998

@article{022c26a2e5bb4a60b9efd99e913f5132,

title = "TSPO Imaging in Glioblastoma Multiforme: A Direct Comparison Between 123I-CLINDE SPECT, 18F-FET PET, and Gadolinium-Enhanced MR Imaging",

abstract = "Here we compare translocator protein (TSPO) imaging using 6-chloro-2-(4′-123I-iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide SPECT (123I-CLINDE) and amino acid transport imaging using O-(2-18F-fluoroethyl)-L-tyrosine PET (18F-FET) and investigate whether 123I-CLINDE is superior to 18F-FET in predicting progression of glioblastoma multiforme (GBM) at follow-up. Methods: Three patients with World Health Organization grade IV GBM were scanned with 123I-CLINDE SPECT, 18F-FET PET, and gadoliniumenhanced MR imaging. Molecular imaging data were compared with follow-up gadolinium-enhanced MR images or contrast-enhanced CT scans. Results: The percentage overlap between volumes of interest (VOIs) of increased 18F-FET uptake and 123I-CLINDE binding was variable (12%-42%). The percentage overlap of MR imaging baseline VOIs was greater for 18F-FET (79%-93%) than 123I-CLINDE (15%- 30%). In contrast, VOIs of increased contrast enhancement at followup compared with baseline overlapped to a greater extent with baseline 123I-CLINDE VOIs than 18F-FET VOIs (21% vs. 8% and 72% vs. 55%). Conclusion: Our preliminary results suggest that TSPO brain imaging in GBM may be a useful tool for predicting tumor progression at followup and may be less susceptible to changes in blood-brain barrier permeability than 18F-FET. Larger studies are warranted to test the clinical potential of TSPO imaging in GBM, including presurgical planning and radiotherapy.",

keywords = "Aged, Bicyclo Compounds, Heterocyclic, Biomarkers, Tumor, Brain Neoplasms, Female, Fluorodeoxyglucose F18, Gadolinium, Glioblastoma, Humans, Image Interpretation, Computer-Assisted, Magnetic Resonance Imaging, Male, Middle Aged, Molecular Imaging, Radiopharmaceuticals, Receptors, GABA, Reproducibility of Results, Sensitivity and Specificity, Tissue Distribution, Tomography, Emission-Computed, Tyrosine",

author = "Per Jensen and Ling Feng and Ian Law and Claus Svarer and Knudsen, {Gitte M} and Mikkelsen, {Jens D} and {de Nijs}, Robin and Larsen, {Vibeke A} and Agnete Dyssegaard and Gerda Thomsen and Walter Fischer and Denis Guilloteau and Pinborg, {Lars H}",

note = "{\textcopyright} 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.",

year = "2015",

month = sep,

day = "1",

doi = "10.2967/jnumed.115.158998",

language = "English",

volume = "56",

pages = "1386--90",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine",

number = "9",

}

TY - JOUR

T1 - TSPO Imaging in Glioblastoma Multiforme

T2 - A Direct Comparison Between 123I-CLINDE SPECT, 18F-FET PET, and Gadolinium-Enhanced MR Imaging

AU - Jensen, Per

AU - Feng, Ling

AU - Law, Ian

AU - Svarer, Claus

AU - Knudsen, Gitte M

AU - Mikkelsen, Jens D

AU - de Nijs, Robin

AU - Larsen, Vibeke A

AU - Dyssegaard, Agnete

AU - Thomsen, Gerda

AU - Fischer, Walter

AU - Guilloteau, Denis

AU - Pinborg, Lars H

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Here we compare translocator protein (TSPO) imaging using 6-chloro-2-(4′-123I-iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide SPECT (123I-CLINDE) and amino acid transport imaging using O-(2-18F-fluoroethyl)-L-tyrosine PET (18F-FET) and investigate whether 123I-CLINDE is superior to 18F-FET in predicting progression of glioblastoma multiforme (GBM) at follow-up. Methods: Three patients with World Health Organization grade IV GBM were scanned with 123I-CLINDE SPECT, 18F-FET PET, and gadoliniumenhanced MR imaging. Molecular imaging data were compared with follow-up gadolinium-enhanced MR images or contrast-enhanced CT scans. Results: The percentage overlap between volumes of interest (VOIs) of increased 18F-FET uptake and 123I-CLINDE binding was variable (12%-42%). The percentage overlap of MR imaging baseline VOIs was greater for 18F-FET (79%-93%) than 123I-CLINDE (15%- 30%). In contrast, VOIs of increased contrast enhancement at followup compared with baseline overlapped to a greater extent with baseline 123I-CLINDE VOIs than 18F-FET VOIs (21% vs. 8% and 72% vs. 55%). Conclusion: Our preliminary results suggest that TSPO brain imaging in GBM may be a useful tool for predicting tumor progression at followup and may be less susceptible to changes in blood-brain barrier permeability than 18F-FET. Larger studies are warranted to test the clinical potential of TSPO imaging in GBM, including presurgical planning and radiotherapy.

AB - Here we compare translocator protein (TSPO) imaging using 6-chloro-2-(4′-123I-iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide SPECT (123I-CLINDE) and amino acid transport imaging using O-(2-18F-fluoroethyl)-L-tyrosine PET (18F-FET) and investigate whether 123I-CLINDE is superior to 18F-FET in predicting progression of glioblastoma multiforme (GBM) at follow-up. Methods: Three patients with World Health Organization grade IV GBM were scanned with 123I-CLINDE SPECT, 18F-FET PET, and gadoliniumenhanced MR imaging. Molecular imaging data were compared with follow-up gadolinium-enhanced MR images or contrast-enhanced CT scans. Results: The percentage overlap between volumes of interest (VOIs) of increased 18F-FET uptake and 123I-CLINDE binding was variable (12%-42%). The percentage overlap of MR imaging baseline VOIs was greater for 18F-FET (79%-93%) than 123I-CLINDE (15%- 30%). In contrast, VOIs of increased contrast enhancement at followup compared with baseline overlapped to a greater extent with baseline 123I-CLINDE VOIs than 18F-FET VOIs (21% vs. 8% and 72% vs. 55%). Conclusion: Our preliminary results suggest that TSPO brain imaging in GBM may be a useful tool for predicting tumor progression at followup and may be less susceptible to changes in blood-brain barrier permeability than 18F-FET. Larger studies are warranted to test the clinical potential of TSPO imaging in GBM, including presurgical planning and radiotherapy.

KW - Aged

KW - Bicyclo Compounds, Heterocyclic

KW - Biomarkers, Tumor

KW - Brain Neoplasms

KW - Female

KW - Fluorodeoxyglucose F18

KW - Gadolinium

KW - Glioblastoma

KW - Humans

KW - Image Interpretation, Computer-Assisted

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Molecular Imaging

KW - Radiopharmaceuticals

KW - Receptors, GABA

KW - Reproducibility of Results

KW - Sensitivity and Specificity

KW - Tissue Distribution

KW - Tomography, Emission-Computed

KW - Tyrosine

U2 - 10.2967/jnumed.115.158998

DO - 10.2967/jnumed.115.158998

M3 - Comment/debate

C2 - 26182972

SN - 0161-5505

VL - 56

SP - 1386

EP - 1390

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 9

ER -